A Phase 3, Multi-center, Open-label Study To Investigate Safety, Efficacy, And Tolerability Of Sildenafil Citrate In Pediatric Patients With Pulmonary Arterial Hypertension
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Sildenafil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors Pfizer
- 23 Feb 2018 Planned End Date changed from 10 Apr 2018 to 1 Mar 2018.
- 10 Jan 2018 Planned End Date changed from 30 Dec 2017 to 10 Apr 2018.
- 10 Jun 2017 Biomarkers information updated